A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.

Abstract

BACKGROUND:

This phase I/II study was designed to determine the maximum tolerated dose of tivantinib in combination with standard dose FOLFOX for the treatment of patients with advanced solid tumors and to evaluate the safety and efficacy of this combination for patients with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach.

METHODS:

Patients with advanced solid tumors for which FOLFOX would be appropriate chemotherapy received escalating doses of tivantinib BID (days 1-14) in a standard 3 + 3 design in phase I. In phase II, patients with advanced GE cancer received standard FOLFOX day 1 and tivantinib (360 mg PO BID) days 1-14 of each 2-week cycle. Restaging occurred every four cycles. The primary phase II endpoint was response rate (RR).

RESULTS:

Forty-nine patients were enrolled (15 on phase I and 34 on phase II). The expansion dose was established as tivantinib 360 mg BID in combination with FOLFOX. Thirty-two phase II patients were treated for a median of eight cycles (range, 1-38), with an overall RR of 38%. Treatment-related toxicities included neutropenia, fatigue, diarrhea, nausea, and peripheral neuropathy. Median progression-free survival (PFS) was 6.1 hmonths with a median time to progression of 7.0 months. Median overall survival was 9.6 months. Two patients remain on study at the time of this analysis.

CONCLUSIONS:

The combination treatment of tivantinib plus FOLFOX in patients with advanced GE cancer showed a response and PFS in the range of historical controls for first-line FOLFOX therapy. However, two patients had extended time on study treatment (36 and 45 cycles) at the time of data cutoff.

• Authors: Shubham Pant, Manish Patel, Carla Kurkjian, Brian Hemphill, Maria Flores, Dana Thompson, Johanna Bendell
• Journal: Cancer investigation (Cancer Invest) Vol. 35 Issue 7 Pg. 463-472 (Aug 09 2017) ISSN: 1532-4192 [Electronic] England
• PMID: 28662341 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study)

Chemical References

• ARQ 197
• Organoplatinum Compounds
• Protein Kinase Inhibitors
• Pyrrolidinones
• Quinolines
• MET protein, human
• Proto-Oncogene Proteins c-met
• Leucovorin
• Fluorouracil

Topics

• Adenocarcinoma (drug therapy, enzymology, secondary)
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
• Disease-Free Survival
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Esophageal Neoplasms (drug therapy, enzymology, pathology)
• Esophagogastric Junction (drug effects, enzymology, pathology)
• Female
• Fluorouracil (administration & dosage, adverse effects)
• Humans
• Kaplan-Meier Estimate
• Leucovorin (administration & dosage, adverse effects)
• Male
• Maximum Tolerated Dose
• Middle Aged
• Organoplatinum Compounds (administration & dosage, adverse effects)
• Protein Kinase Inhibitors (administration & dosage, adverse effects)
• Proto-Oncogene Proteins c-met (antagonists & inhibitors, metabolism)
• Pyrrolidinones (administration & dosage, adverse effects)
• Quinolines (administration & dosage, adverse effects)
• Signal Transduction (drug effects)
• Stomach Neoplasms (drug therapy, enzymology, pathology)
• Time Factors
• Treatment Outcome
• United States